Elidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitis
Authors:
- Lisa BeckLBLisa Beck
- 1 May 2003
- journal article
- review article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 111 (5) , 1153-1168
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Pimecrolimus Identifies a Common Genomic Anti-inflammatory Profile, is Clinically Highly Effective in Psoriasis and is Well ToleratedJournal of Investigative Dermatology, 2002
- The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophilsJournal of Allergy and Clinical Immunology, 2001
- Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitisJournal of the American Academy of Dermatology, 2001
- Disease Management of Atopic Dermatitis: a Practice ParameterAnnals of Allergy, Asthma & Immunology, 1997
- Unbalanced Production of Interleukin-5 and Interleukin-2 in Children with Atopic DermatitisAnnals of Allergy, Asthma & Immunology, 1997
- Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitisBritish Journal of Dermatology, 1997
- Indications for Tacrolimus anti-rejection therapy in liver allograft recipientsTransplant International, 1996
- Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis.Journal of Clinical Investigation, 1994
- The involvement of eosinophils in the patch test reaction to aeroallergens in atopic dermatitis: its relevance for the pathogenesis of atopic dermatitisClinical & Experimental Allergy, 1993
- Pathogenesis of eczemaClinical & Experimental Allergy, 1990